P177

WORK PARTICIPATION IN PATIENTS WITH SYSTEMATIC LUPUS ERYTHEMATOSUS: A SCOPING REVIEW

¹Birgit Blomjous, ²Gayle Gajadin, ¹Irene Bultink, ¹Alexandre Voskuyl, ³Louise Falzon, ⁴Jan Hoving, ¹, ²Marieke ter Wee. ¹Dept. of Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam; ²Dept. of Epidemiology and Biostatistics, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; ³Center for Personalized Health, Feinstein Institutes for Medical Research, Northwell Health, New York, USA; ⁴Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

10.1136/lupus-2020-eurolupus.219

Background The treatment of Systemic Lupus Erythematosus (SLE) has improved over the last decades. However, patients are more vulnerable for sick leave, work disability and unemployment compared to the general population. It is therefore important to understand the magnitude of the problem and the factors that might affect work participation in patients with SLE, to evaluate which actions can be taken to limit the burden on a patient and society level. The aim of this research is to summarize the existing literature on 1) the prevalence of work disability, 2) prognostic factors for work participation and 3) the effectiveness of interventions to improve work participation in patients with SLE.

Methods A scoping review, using the PRISMA-ScR statement will be conducted. Full-text original articles published before April 2019 were identified by literature search performed in MEDLINE, Cochrane, Embase and CINAHL. Articles in all languages, concerning work participation in patients with SLE, aged ≥ 18 years were included.

Results In total, 2050 non-duplicate citations were screened. After title/abstract screening, 75 articles were retrieved. Relevant articles will be identified and reference lists will be searched for additional articles by two independent researchers. Information on author(s), year of publication, study location, intervention type, comparator, duration of the intervention, study population, aims of the study, methodology, outcome measures and important results will be collected. The results will be presented at the congress.

Conclusion Based on this scoping review, implications for future research including a research agenda and daily practice will be identified.

P178

LUPUS NEPHRITIS WAS ASSOCIATED WITH LOW BONE MINERAL DENSITY IRRESPECTIVE OF DURATION ON STEROID TREATMENT IN A LARGE UK STUDY OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS

¹Anastasia-Vasiliki Madenidou, ^{1,2}Yasmin Mahfouz, ^{1,2}Oliver Chang, ^{1,2}Farah El-Sharnoubi, ¹Charlene Foley, ¹Coziana Ciurtin. ¹Centre for Adolescent Rheumatology, University College London, London; ²University College London Medical School, London, UK

10.1136/lupus-2020-eurolupus.220

Background Estimated 10–20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified as juvenile-onset SLE (JSLE). JSLE patients have a higher prevalence of lupus nephritis (LN) compared to adult-onset SLE¹ and decreased long-term survival compared to JSLE patients without LN.² We aimed to identify clinical and laboratory predictors of LN

in JSLE patients by comparing the baseline characteristics of JSLE patients with and without LN.

Methods This is a single-center retrospective study, who included JSLE patients reviewed in our young adult and adolescent clinics after transitioning from paediatric services. All data have been analyzed descriptively. Mann-Whitney U or Chi-square test were performed to compare the characteristics between the patients with and without LN. In addition, we performed uni and multivariate analysis to investigate potential predictor biomarkers for LN.

Results We identified 134 JSLE patients, out of which 45 (34%) had LN. The baseline characteristics are detailed in table 1. As expected, the highest dsDNA levels ever were found in patients with LN ($p=0.022$). Patients with LN also had longer disease duration ($p=0.012$). The overall clinical manifestations and complications did not differ between JSLE patients with or without LN, except for the prevalence of low

Abstract P178 Table 1 Baseline characteristics

	Lupus nephritis	Without Lupus nephritis	P value
Number of patients, n (%)	45 (36%)	89 (66.4%)	
Female	39 (86.7%)	73 (82%)	0.624
Age, years	22 (21- 26)	21 (19- 25)	0.092
Age at diagnosis, years	13 (10- 15)	13 (11.25- 15)	0.471
Age at menarche, years	12.75 (11.25- 15.75)	12.25 (11- 14.38)	0.543
Disease duration, years	10 (8- 14)	8 (6- 13)	0.012*
BMI, kg/m ²	24.31 (20.41- 26.13)	23.96 (21.69- 28.5)	0.726
ANA	38 (84.4%)	85 (95.5%)	0.064
ENA	24 (53.3%)	51 (57.3%)	0.114
Anti- Ro	15 (33.3%)	31 (34.8%)	0.134
Anti- La	6 (13.3%)	14 (15.7%)	0.130
RF	3 (6.7%)	18 (20.2%)	0.114
Highest dsDNA levels ever	197 (32- 434)	48 (10- 294)	0.022*

Numbers are medians (interquartile ranges) unless otherwise stated. * $p<0.05$ is significant

Abstract P178 Table 2 Clinical manifestations and complications

	Lupus nephritis	Without Lupus nephritis	P value
Number of patients, n (%)	45 (36%)	89 (66.4%)	
SLICC at last clinical assessment	0	0 (0- 0.5)	0.872
SLEDAI at last clinical assessment	2 (0- 4)	0 (0- 2)	0.123
BILAG at last clinical assessment	1 (0- 1.75)	1 (0- 1)	0.822
Constitutional symptoms	26 (80%)	67 (75.3%)	0.666
Mouth ulcers	31 (68.8%)	61 (68.5%)	0.258
Skin involvement	40 (88.9%)	73 (82%)	0.150
Arthritis	37 (82.2%)	71 (79.8%)	0.309
Myositis	5 (11.1%)	16 (18%)	0.451
Neuropsychiatric involvement	15 (33.3%)	19 (21.3%)	0.146
Cardiorespiratory involvement	12 (26.7%)	20 (22.5%)	0.669
Gastrointestinal involvement	8 (17.8%)	18 (20.2%)	0.724
Ophthalmic involvement	4 (8.9%)	9 (10.1%)	0.108
Haematological involvement	26 (57.8%)	44 (49.4%)	0.464
Hypertension	8 (17.8%)	6 (6.7%)	0.071
Stroke	1 (2.2%)	2 (2.2%)	1.000
Low bone mineral density	16 (35.5%)	11 (12.4%)	0.008*
Malignancy	1 (2.2%)	1 (1.1%)	1.000

Numbers are medians (interquartile ranges) unless otherwise stated. * $p<0.05$ is significant

Abstract P178 Table 3 Treatment differences among JSLE patients

	Lupus nephritis	Without Lupus nephritis	p
Number of patients, n (%)	45 (36%)	89 (66.4%)	
Hydroxychloroquine, n (%)	43 (95.6%)	88 (98.9%)	0.295
Steroid treatment duration, (months)	31 (1.5- 84.5)	29.5 (9- 54.8)	0.834
MMF, n (%)	39 (86.7%)	43 (48.3%)	0.000*
MMF, months	42 (18.75- 94.5)	0 (0- 44)	0.000*
Cyclophosphamide, n (%)	22 (48.9%)	17 (19.1%)	0.001*
Cyclophosphamide, number of courses	0 (0- 3)	0	0.000*
Rituximab, n (%)	27 (60%)	29 (32.6%)	0.003*
Rituximab, number of courses	2 (0- 2)	0 (0- 1)	0.000*
Azathioprine, months	2.5 (0- 48.5)	10 (0- 41)	0.868
Methotrexate, months	0	0 (0- 0.75)	0.529
Tacrolimus, months	0	0	0.219
Belimumab, months	0	0	0.310

Numbers are medians (interquartile ranges) unless otherwise stated. MMF= mycophenolate mofetil. *p<0.05 is significant

bone mineral density (table 2). Factors associated with low bone mineral density in a univariate logistic regression analysis were: the use of mycophenolate mofetil ($p=0.021$) and the presence of LN ($p=0.007$), while LN also associated with low bone density ($p=0.008$) in a multivariate analysis. The skin involvement was the most common clinical manifestation in both JSLE patient groups. The treatment was more aggressive in patients with LN, including the use of cyclophosphamide, mycophenolate and rituximab, but there was no difference regarding the length of the steroid treatment (table 3). The majority of the patients (67%) had one flare of nephritis and the number of flares ranged from 2 (13%) to 12 (2.2%) for the rest of the patients in this cohort with disease duration ranging from 8–12 years. The class of nephritis was reported in 34 out of 45 patients, and focal lupus nephritis (class III) was the most common type (44%). There were no statistical significant differences in the baseline characteristics or treatments among the different classes of LN.

Conclusion Low bone mineral density is common in patients with JSLE³, but this is the first study highlighting the association of low bone density with LN and the lack of association with the total duration of steroid treatment or other clinical manifestations.

REFERENCES

- Ambrose N, et al. Differences in disease phenotype and severity in SLE across age groups. *Lupus*. 2016;**25**(14):1542–50.
- Smith EMD, et al. Clinical predictors of active LN development in children- evidence from the UK JSLE Cohort Study.
- Compeyrot-Lacassagne S, et al. Prevalence and etiology of low bone mineral density in Juvenile Systemic Lupus Erythematosus.

P179 SYSTEMIC LUPUS ERYTHEMATOSUS, A PILOT STUDY OF A NEW DISEASE ACTIVITY SCORE

¹Daphna Paran, ¹Monique Ben-Am, ¹Liran Mendel, ¹Ari Polachek, ¹Victoria Furer, ¹Ofir Elalouf, ¹Jonathan Wollman, ²Shaye Kivity, ³Nancy Agmon-Levin. ¹Dept. of Rheumatology, Tel Aviv Medical Center; ²Dept. of Medicine 'A', Sheba Medical Center; ³Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center and Tel-Aviv University, Israel

10.1136/lupus-2020-eurolupus.221

Background SLE complexity and unpredictability challenge assessment of disease activity. Current scoring instruments are limited in ability to detect changes in activity over time and too cumbersome for daily practice. We constructed a new disease activity score, including physician and patient assessment, aiming to simplify and improve assessment in daily practice, and possibly serve as a tool for clinical studies.

Methods The new instrument is comprised of 6 visual analogue scales, separately addressing the physician's global assessment and 5 organ systems: mucocutaneous, musculoskeletal, cardiorespiratory, renal and neuropsychiatric systems, and 5 visual analogue scales addressing patients' assessment of disease activity and adherence to therapy. Laboratory values and medications are recorded. Aiming to assess the reliability and validity of the new score, as well as its sensitivity to changes in disease activity, 4 paper cases, including 2 visits per case, were constructed. Each visit was scored by 5 experienced rheumatologists, using BILAG, SLEDAI, LFA-REAL and our proposed score.

Results The inter-rater reliability of the new score was good for all systems, both for single visit scores and for change in disease activity between 2 consecutive visits (ICC [2,1] range 0.75–0.95), except for changes in activity in the renal system (0.59). The inter-rater reliability values of the new score were comparable with those of the BILAG and the LFA-REAL instruments. The construct validity of the new score was good for single visit scores (Spearman correlation coefficients range 0.48–0.94). Correlation of our proposed score with the BILAG, was good when scoring the mucocutaneous, musculoskeletal and cardiorespiratory systems (0.66, 0.75, 0.83, respectively) but poor when scoring the renal system (0.11).

Conclusions This paper case evaluation of the new disease activity score suggests a promising and simple tool, with overall good reliability and construct validity.

P180 CORRELATION BETWEEN PATIENT REPORTED OUTCOMES OF HEALTH-RELATED QUALITY OF LIFE AND CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

¹Elena Grau-García, ¹Samuel Leal-Rodríguez, ¹Cristóbal Pávez-Perales, ¹Cristina Alcañiz-Escandell, ¹Inés Cánovas-Olmos, ¹Inmaculada Chalmeta-Verdejo, ¹Marta De-la-Rubia-Navarro, ¹Jorge Juan Frago-Gil, ¹Roxana González-Mazarío, ¹Luis González-Puig, ¹José Ivorra-Cortés, ¹Isabel Martínez-Cordellat, ¹Carmen Nájera-Herranz, ¹Rosa Neguerolles-Albuixech, ¹José Eloy Oller-Rodríguez, ¹Francisco Miguel Ortiz-Sanjuán, ¹Elvira Vicens-Bernabeu, ²Daniel Hervás-Marín, ¹José Andrés Román-Ivorra. ¹Rheumatology Dept., Hospital Universitario y Politécnico de La Fe, Valencia; ²Biostatistics Unit. Instituto de Investigación Sanitaria La Fe, Valencia, Spain

10.1136/lupus-2020-eurolupus.222

Background/Purpose Patient-Reported Outcomes (PROs) allow us to know how the disease could affect patients, and maybe could not be detected by clinical measures. Among these, PROs of health-related quality of life (PRO-QL) represents patient evaluation of its health status. In systemic lupus erythematosus (SLE) patients, the heterogeneous inflammatory symptoms can affect the health-related quality of life in different ways.

We aimed to measure the PRO-QL in SLE patients and correlate them with the clinical activity of the disease.

Methods A cross-sectional observational study with SLE patients diagnosed according to SLICC 2012 criteria was performed. SLEDAI score was carried out, and patients full-filled